226 related articles for article (PubMed ID: 23406775)
1. Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent.
Pinto EM; Morton C; Rodriguez-Galindo C; McGregor L; Davidoff AM; Mercer K; Debelenko LV; Billups C; Ribeiro RC; Zambetti GP
Clin Cancer Res; 2013 Apr; 19(7):1740-7. PubMed ID: 23406775
[TBL] [Abstract][Full Text] [Related]
2. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
3. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
4. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
5. Update on in-vivo preclinical research models in adrenocortical carcinoma.
Kar A; Wierman ME; Kiseljak-Vassiliades K
Curr Opin Endocrinol Diabetes Obes; 2020 Jun; 27(3):170-176. PubMed ID: 32304391
[TBL] [Abstract][Full Text] [Related]
6. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma.
Satoh K; Zhang L; Zhang Y; Chelluri R; Boufraqech M; Nilubol N; Patel D; Shen M; Kebebew E
Clin Cancer Res; 2016 Jul; 22(14):3458-66. PubMed ID: 26873959
[TBL] [Abstract][Full Text] [Related]
7. microRNA-431 as a Chemosensitizer and Potentiator of Drug Activity in Adrenocortical Carcinoma.
Kwok GTY; Zhao JT; Glover AR; Gill AJ; Clifton-Bligh R; Robinson BG; Ip JCY; Sidhu SB
Oncologist; 2019 Jun; 24(6):e241-e250. PubMed ID: 30918109
[TBL] [Abstract][Full Text] [Related]
8. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
9. Chloroquine enhances the efficacy of cisplatin by suppressing autophagy in human adrenocortical carcinoma treatment.
Qin L; Xu T; Xia L; Wang X; Zhang X; Zhang X; Zhu Z; Zhong S; Wang C; Shen Z
Drug Des Devel Ther; 2016; 10():1035-45. PubMed ID: 27022243
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study.
Wasserman JD; Novokmet A; Eichler-Jonsson C; Ribeiro RC; Rodriguez-Galindo C; Zambetti GP; Malkin D
J Clin Oncol; 2015 Feb; 33(6):602-9. PubMed ID: 25584008
[TBL] [Abstract][Full Text] [Related]
11. IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.
Beuschlein F; Jakoby J; Mentz S; Zambetti G; Jung S; Reincke M; Süss R; Hantel C
Mol Cell Endocrinol; 2016 Jun; 428():82-8. PubMed ID: 26994514
[TBL] [Abstract][Full Text] [Related]
12. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment.
Lang J; Capasso A; Jordan KR; French JD; Kar A; Bagby SM; Barbee J; Yacob BW; Head LS; Tompkins KD; Freed BM; Somerset H; Clark TJ; Pitts TM; Messersmith WA; Eckhardt SG; Wierman ME; Leong S; Kiseljak-Vassiliades K
J Clin Endocrinol Metab; 2020 Jan; 105(1):26-42. PubMed ID: 31513709
[TBL] [Abstract][Full Text] [Related]
13. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
14. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.
Ross JS; Wang K; Rand JV; Gay L; Presta MJ; Sheehan CE; Ali SM; Elvin JA; Labrecque E; Hiemstra C; Buell J; Otto GA; Yelensky R; Lipson D; Morosini D; Chmielecki J; Miller VA; Stephens PJ
J Clin Pathol; 2014 Nov; 67(11):968-73. PubMed ID: 25078331
[TBL] [Abstract][Full Text] [Related]
16. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation.
Hui W; Liu S; Zheng J; Fang Z; Ding Q; Feng C
Cancer Med; 2018 Apr; 7(4):1440-1449. PubMed ID: 29532999
[TBL] [Abstract][Full Text] [Related]
17. Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
Luconi M; Mannelli M
Mol Cell Endocrinol; 2012 Mar; 351(1):71-7. PubMed ID: 22056412
[TBL] [Abstract][Full Text] [Related]
18. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC.
Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K
Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906
[TBL] [Abstract][Full Text] [Related]
19. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.
Cheng Y; Kerppola RE; Kerppola TK
Endocr Relat Cancer; 2016 Apr; 23(4):1-19. PubMed ID: 26843528
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]